“This gene-to-molecule research is crucial for discovery in Alzheimer’s disease. It offers fresh perspectives on how genetic risk factors, such as APOE, influence metabolism and perhaps disease ...
The hotspot at chr3q28 sits between the GMNC and osteocrin (OSTN) genes. They are involved in DNA replication and dendritic ...
Brain age gap (BAG) is a useful metric because it predicts one’s age-adjusted vulnerability to a range of neurological disorders, such as AD, dementia, and stroke. Although brain age may indeed ...
Strapped with an extra APP, people with Down’s syndrome are all but destined to develop Alzheimer’s dementia if they live ...
“The astrocyte response to AD neuropathology is complex and nonlinear, both along spatial and temporal axes,” Das told Alzforum. She hopes the dataset, which is freely available online, will be a ...
Just as Eisai notches wins in its campaign for lecanemab approval around the world—last month in the European Union, this week in Mexico—a dozen research and clinical leaders called on the U.S. FDA ...
Tapering. Spaghetti plots show that CSF NFL (right) rises more quickly in people with ADAD mutations (red) than in noncarriers (gray) and that this accelerates as disease progresses. In plasma (left), ...
Mivelsiran docks APP products in early AD. Phase 2 trial asks: Can it treat CAA? LX1001 gene therapy boosts CSF ApoE2, stabilizes AD biomarkers. Intranasal insulin quells systemic inflammation. These ...
What if there were a way to triple the speed of MRI scans without losing resolution? At the Clinical Trials on Alzheimer’s Disease conference, held October 29 to November 1 in Madrid, Miguel ...
Alzheimer’s disease is a long, slow neurodegenerative calamity, and scientists are still hunting for blood biomarkers that reflect all its specific stages. At the Clinical Trials on Alzheimer’s ...
Yes, blood tests for Alzheimer’s disease are ready for prime time. So pronounced Suzanne Schindler, Washington University, St. Louis, in a keynote presentation at CTAD 2024 last month in Madrid. In ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback